How much does Mounjaro reduce birth control hormone levels?

In the drug interaction study reported in the Mounjaro label, a single 5 mg dose of tirzepatide taken with a combined pill containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate lowered peak concentrations of ethinyl estradiol by 59%, norgestimate by 66%, and norelgestromin by 55%. Total exposure (AUC) fell by 20%, 21%, and 23%, and the time to peak was delayed by 2.5 to 4.5 hours.

Which birth control methods are safe to use with Mounjaro?

The label's instruction applies only to oral hormonal contraceptives. Non-oral methods such as hormonal or copper IUDs, the implant, the contraceptive injection, the patch, and the vaginal ring do not pass through the stomach, so delayed gastric emptying does not affect them. Condoms count as the barrier method the label allows as an alternative.

Does Ozempic affect birth control pills the same way?

No. The Ozempic (semaglutide) label states that semaglutide did not affect the absorption of oral medications to any clinically relevant degree, and it reports no clinically relevant change in ethinyl estradiol or levonorgestrel exposure. The Ozempic label has no instruction to switch methods or add a barrier. A 2024 review found that only tirzepatide, not the GLP-1 receptor agonists, significantly lowered oral contraceptive hormone levels.

Can you take Mounjaro while pregnant or trying to conceive?

The Mounjaro label says human data are insufficient to evaluate the risk of birth defects or miscarriage, and animal studies suggest there may be risks to the fetus. The Zepbound label, for the same molecule, directs patients to stop when a pregnancy is recognized. The Mounjaro label gives no washout period before a planned pregnancy; the UK FSRH lists one month for tirzepatide. Talk to your prescriber before trying to conceive.

Does Mounjaro Make Birth Control Pills Less Effective?

Q: Does Mounjaro make birth control pills less effective?

It can. The FDA-approved Mounjaro label states that tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying. The label advises patients on birth control pills to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.

The short answer: yes, it can. The FDA-approved Mounjaro label tells patients on oral hormonal contraceptives to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. The reason is that tirzepatide slows stomach emptying, and in a pharmacokinetic study a single 5 mg dose cut the peak blood level of ethinyl estradiol by 59%. Pills are the only form of birth control the label calls out. IUDs, implants, injections, the patch, and the ring do not pass through the stomach and carry no such instruction.

What does the Mounjaro label say about birth control pills?

The instruction appears three times in the MOUNJARO prescribing information: in drug interactions (7.2), in the section on females of reproductive potential (8.3), and in patient counseling (17). Section 8.3 puts it this way:

Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO.

The Zepbound label carries the same instruction, because Zepbound is the same molecule at the same doses. The wording covers "oral hormonal contraceptives" as a group. That includes combined pills (estrogen plus progestin) and progestin-only pills. The label does not distinguish between them.

How much does Mounjaro lower birth control hormone levels?

The label's clinical pharmacology section (12.3) reports a drug interaction study. Participants took a combined oral contraceptive containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate together with a single 5 mg dose of tirzepatide. According to a 2024 review in the Journal of the American Pharmacists Association (Skelley and colleagues), the study enrolled 40 women. The results in the label:

Ethinyl estradiol: peak concentration (Cmax) down 59%, total exposure (AUC) down 20%.
Norgestimate: Cmax down 66%, AUC down 21%.
Norelgestromin (the active metabolite of norgestimate): Cmax down 55%, AUC down 23%.
Time to peak (tmax) delayed by 2.5 to 4.5 hours for all three.

Peak concentrations dropped by more than half, but total exposure fell only about one fifth. That is the pattern of slowed absorption, not blocked absorption: the hormone still gets in, but later and with a flatter peak. No trial has measured pregnancy rates in women taking both drugs, so the recommendation rests on blood levels, not on outcome data.

Why 4 weeks, and why again after each dose increase?

The label's pharmacodynamics section (12.2) gives the reason: "Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time." The stomach adapts to a given dose over the following weeks. Each time the dose goes up, the slowing effect returns, then fades again. The 4-week window matches the label's minimum interval between dose steps.

Per the label, Mounjaro starts at 2.5 mg once weekly for 4 weeks, then moves to 5 mg, and can increase in 2.5 mg steps after at least 4 weeks on each dose, up to 15 mg. A patient who climbs from 2.5 mg to 15 mg on the shortest schedule goes through initiation plus five escalations. Under the label's rule, that patient would use a backup or non-oral method for the whole 24-week titration. Our Mounjaro dosing schedule guide lays out each step, and the dosing page covers the label's titration rules.

After 4 weeks on the same dose, the label's instruction lapses. Vomiting and diarrhea can still interfere with pill absorption at any dose.

What if Mounjaro causes vomiting or diarrhea?

Nausea, vomiting, and diarrhea are among the most common Mounjaro side effects. The label states that most reports occurred during dose escalation and decreased over time. They matter for pill users on their own. The CDC's 2024 U.S. Selected Practice Recommendations for Contraceptive Use state that vomiting or severe diarrhea while using combined oral contraceptives might reduce their effectiveness, and it bases its guidance on the missed-pill rules: take the next pill as soon as tolerated and use a backup method until pills have been taken for 7 consecutive days without vomiting or severe diarrhea.

The UK Faculty of Sexual and Reproductive Healthcare (FSRH) statement from January 2025 adds one step: if vomiting or diarrhea is persistent on a GLP-1 medication, consider a non-oral method. If you also miss a Mounjaro injection during this period, our missed dose guide explains the label's 4-day rule.

Which birth control methods are not affected?

The label's fix is a "non-oral contraceptive method." Hormonal IUDs, copper IUDs, the implant, the contraceptive injection, the patch, and the vaginal ring all work without passing through the stomach, so delayed gastric emptying does not apply to them. Condoms count as a barrier method under the label's wording, and the label allows either option: switch, or add a barrier. The FSRH advises that anyone on any GLP-1 medication use contraception, since none of these drugs has pregnancy safety data.

Does Ozempic carry the same warning?

No. The Ozempic (semaglutide) label says in section 7.2 that semaglutide "did not affect the absorption of orally administered medications to any clinically relevant degree," and its clinical pharmacology section reports no clinically relevant change in ethinyl estradiol or levonorgestrel exposure at steady state. The Ozempic label contains no instruction to switch methods or add a barrier.

The Skelley review found the same split across the drug class. Of six pharmacokinetic studies, only the tirzepatide study showed a statistically significant drop in contraceptive hormone levels. The five GLP-1 receptor agonist studies did not. The FSRH puts it plainly: tirzepatide is the only drug in this group with a clinically significant effect on oral contraceptive bioavailability, and no barrier method is needed with semaglutide, dulaglutide, exenatide, lixisenatide, or liraglutide. For more on semaglutide, see our sister site ozempic.md.

What does the label say about pregnancy on Mounjaro?

The Mounjaro label's pregnancy section (8.1) states that available human data are insufficient to evaluate a drug-related risk of major birth defects or miscarriage, and that animal studies suggest there may be risks to the fetus. The Zepbound label goes further, because it is approved for weight loss: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm," and it directs patients to stop Zepbound when a pregnancy is recognized.

On stopping before a planned pregnancy, the labels differ. The Ozempic label tells women to discontinue at least 2 months before a planned pregnancy because of semaglutide's long washout. The Mounjaro label contains no equivalent instruction. The FSRH statement lists a washout of one month for tirzepatide and two months for semaglutide. Discuss timing with your prescriber before trying to conceive.

Then there is the phenomenon the press calls "Ozempic babies": unexpected pregnancies after starting a GLP-1 medication. UT Southwestern's obstetrics team describes the likely mechanism. Weight loss of about 10% of body weight can restore regular cycles and ovulation in women whose fertility was suppressed by obesity or insulin resistance, which is common in PCOS. A 2025 review in Clinical Medicine (Varughese and colleagues) reports that GLP-1 medications improve menstrual regularity and ovulation in women with obesity and PCOS. Add reduced pill absorption on tirzepatide, and the risk of an unplanned pregnancy is real. Our Mounjaro and PCOS guide covers this population in more detail.

If a pregnancy does occur, the human data are early. The Varughese review cites a prospective study of 168 women exposed to a GLP-1 medication in the first trimester. It found no specific pattern of birth defects and a major malformation rate of 2.6%, versus 2.3% and 3.9% in two comparison groups. Those numbers are small, and the FDA still classifies the risk as unknown. Stop the drug when pregnancy is recognized and call your prescriber.

The bottom line

Mounjaro can make birth control pills less reliable. The label's rule is specific: use a non-oral method or add a barrier for 4 weeks after starting and 4 weeks after every dose increase. The basis is a 55% to 66% drop in peak hormone levels after a single 5 mg dose. The Ozempic label does not carry this warning.

If you take the pill and are starting Mounjaro, the simplest option is an IUD, implant, injection, patch, or ring before your first dose. If you stay on the pill, use condoms through every 4-week window and treat vomiting or diarrhea as a missed pill. Mounjaro is not recommended in pregnancy, and weight loss on it can restore fertility. Plan for that.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. It summarizes FDA-approved labeling and published guidance; it cannot replace instructions from the clinician who prescribed your medication. Contact your prescriber about contraception, pregnancy planning, or side effects.